GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ORGO · Mar 31, 2024

Organogenesis Holdings Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0000950170-24-057050General Corporate
Debt relative to revenueRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.debt_to_revenue

59.25% · OPTIONAL · NOT_ENOUGH_HISTORY

Capex intensityRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

2.02% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-9.24% · OPTIONAL · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

25.18% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.gross_margin

73.91% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.operating_margin

-3.50% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

11.65% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

2.19% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History11 statesHistory building
Dec 31, 20230/8 normalizedLevel 3Mar 31, 20240/8 normalizedLevel 3Jun 30, 20240/8 normalizedLevel 3Sep 30, 20240/8 normalizedLevel 3Dec 31, 20240/8 normalizedLevel 3Mar 31, 20250/8 normalizedLevel 3Jun 30, 20250/7 normalizedLevel 3Sep 30, 20250/7 normalizedLevel 3Dec 31, 20256/7 normalizedLevel 3Mar 31, 20266/7 normalizedLevel 3Jun 30, 20266/7 normalizedLevel 3
Period transition

What moved in the state?

Balance Sheet Leverage Increased
Previous
15.37%
Current
59.25%
Delta
43.88%
Capex Intensity Decreased
Previous
5.62%
Current
2.02%
Delta
-3.60%
Cash Generation Decreased
Previous
7.14%
Current
-9.24%
Delta
-16.38%
Inventory Pressure Increased
Previous
6.52%
Current
25.18%
Delta
18.66%
Margin Decreased
Previous
75.42%
Current
73.91%
Delta
-1.51%
Profitability Decreased
Previous
2.89%
Current
-3.50%
Delta
-6.39%
R And D Intensity Increased
Previous
10.25%
Current
11.65%
Delta
1.40%
Sbc Intensity Increased
Previous
2.08%
Current
2.19%
Delta
0.11%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · ORGO Fundamental State →Has State · Organogenesis Holdings Inc. →Transitioned To · ORGO Fundamental State →Transitioned To · ORGO BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · ORGO CAPEX_INTENSITY_DECREASED →Transitioned To · ORGO CASH_GENERATION_DECREASED →Transitioned To · ORGO INVENTORY_PRESSURE_INCREASED →Transitioned To · ORGO MARGIN_DECREASED →Transitioned To · ORGO PROFITABILITY_DECREASED →Transitioned To · ORGO R_AND_D_INTENSITY_INCREASED →Transitioned To · ORGO SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.